- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06436937
Protein Quality of Fava Bean and Honey Chlorella in Humans (Giant Leaps)
Protein Quality of Fava Bean Meat Analogue and Honey Chlorella Ingested as Mixed Meals in Healthy Volunteers
Study Overview
Status
Detailed Description
The objective is to determine the nutritional quality of protein from honey chlorella and faba bean meat analogue in healthy humans, especially in terms of protein and amino acid digestibility as well as nitrogen retention. Ileal digestibility is determined in ileal digesta collected postprandially with a naso-ileal tube. The protein sources are intrinsically labelled in 15N in order to track dietary nitrogen and amino acids in the samples.
Ethical and regulatory aspects:
The protocol has been approved to the Ethical Committee and authorized the French Agency of Drugs and Health. The personal data management will be in accordance with the regulation on personal data protection ( " regulation n° 2018-493 du 20 juin 2018").
Meal:
The meal will consist in either a drink containing 40 g of honey chlorella or a mixed meal containiong 80 g of meat analogue, to provide 20 g protein. Sensory tests will be realized to optimize the organoleptic properties of the meal.
Volunteers:
Sixteen subjects will be included in the study. The investigators plan to recruit around 40 volunteers to accommodate for the usual 60% dropouts.
Four days before the experiment, the volunteers will follow a standard diet adapted to their body weight to control their protein intake (1.3 g protein/kg body weight).
The volunteers will arrive at the Human Nutrition Research Centre of Avicenne Hospital on the morning before the day of the experiment. They will be equipped with a double lumen intestinal tube that will be allowed to progress through the intestinal tract for 24h. One of the lumen is radio opaque and serves to perfuse a non-absorbable maker in the intestine (slow marker method). The other lumen is dedicated to the continuous aspiration of the effluents, 15 cm below the perfusion site. The measurement of the non-absorbable marker in the effluents allows the determination of the effluent flow rate.
On the evening before the experimental day, they will ingest 3 oral doses of deuterated water 99 % to reach 5g/kg total body water, to label the intestinal endogenous proteins.
On the day of the experiment, the position of the tube will be checked by radiography to verify its location at the terminal ileum. A catheter will be inserted in the forearm vein for blood sampling. The perfusion of the non-absorbable marker, PEG-4000 (20g/l), will start at a flow rate of 1ml/min. The intestinal flow and the basal ileal sample will be collected during 30 min. Basal plasma sample will be sampled.
Then, at t=0, the volunteers will drink the test-meal. Until t=8h, intestinal content will be continuously collected by aspiration and pooled every 30 minutes. Blood will be sampled every 30 minutes during 4h and hourly thereafter. The urine will be collected every 2 h for 8 h.
Measurements:
In the ilel digesta:
PEG-4000 by turbidimetric method, total N and 15N enrichment by EA-IRMS, amino acid concentrations by UPLC (after acid hydrolysis HCl 6N at 110°C for 24h), 15N amino acid enrichment by GC-c-IRMS (after purification on cation exchange resin and derivatization), 2H amino acid enrichment by GC-c-IRMS, microbiome analysis (DNA sequencing), peptide analysis (LC-MS).
In the plasma:
Glucose, urea (colorimetric methods), insulin (ELISA), amino acid concentrations (UPLC), 15N enrichment in plasma protein, urea and free amino acids (EA-IRMS, after purification on cation exchange resin and derivatization).
In the urine:
Urea (colorimetric method) and 15N urea (EA-IRMS, after purification on cation exchange resin and derivatization).
Main outcomes are:
Real ileal digestibility of protein and amino acids (digestive losses), Postprandial deamination (metabolic losses), Net Postprandial Protein Utilization
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gheorghe Airinei, MD
- Email: gheorghe.airinei@aphp.fr
Study Contact Backup
- Name: Claire Gaudichon, PhD, Prof
- Phone Number: 33189100852
- Email: claire.gaudichon@agroparistech.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Recruiting
- Research Center on Volunteers
-
Contact:
- Claire Gaudichon
- Phone Number: 33 1 89 10 08 52
- Email: claire.gaudichon@agroparistech.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18<BMI<30
- Good health (WHO=0)
- For woman: use of birth control
Exclusion Criteria:
- food allergy
- allergy against latex
- pregnant women
- Positive serology for AgHBS, AcHbc, HCV, HIV
- Anemia
- Excessive alcohool consumption
- Hypertension, diabetes, digestive, hepatic or renal diseases, cardiac disease
- Exercice>7h/week
- Blood donation within 3 months before the study
- Participation to another clinical study within 3 months before the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Honey Chlorella
The subjects ingest a single meal: a drink including 40 g of honey chlorella intrinsically labelled with 15N, to provide 20g protein from chlorella
|
Ingestion of a 15N labeled test meal.
Subjects are equipped with a nasoileal tube.
15N is followed in biological fluids (plasma, effluents, urines).
|
|
Experimental: Faba bean meat analogue
The subjects ingest a single meal: a mixed meal including 80 g of faba bean meat analogue intrinsically labelled with 15N, to provide 20g protein from faba bean
|
Ingestion of a 15N labeled test meal.
Subjects are equipped with a nasoileal tube.
15N is followed in biological fluids (plasma, effluents, urines).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Net Postprandial Protein Utilization (NPPU)
Time Frame: 0 to 8 hours after the test meal
|
The measurement of urea (mmol) and 15N enrichment of urea (atom %) allow to determine the amount of dietary N that was transferred to urea, thus accounting for metabolic losses.
Metabolic losses of dietary N, together with digestive losses of dietary N, are not retained in the body.
|
0 to 8 hours after the test meal
|
|
Ileal digestibility of protein and amino acids
Time Frame: -30 minutes to 8 hours after the test meal
|
The measurement of nitrogen (mmol) and 15N enrichment (atom %) in ileal samples allow to determine the amount of dietary nitrogen in the lumen.
Dietary nitrogen that is recovered in the ileal samples are then considered as non absorbed.
|
-30 minutes to 8 hours after the test meal
|
|
Ileal digestibility of amino acids
Time Frame: -30 minutes to 8 hours after the test meal
|
The measurement of amino acid concentration (mmol) and their individual 15N enrichment (atom %) allow the determination of dietary amino acids remaining in the lumen.
Dietary amino acids that are recovered in the ileal samples are then considered as non absorbed.
|
-30 minutes to 8 hours after the test meal
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nitrogen metabolites in blood in response to the ingestion of 15N fava bean
Time Frame: 0 to 8 hours after the test meal
|
urea and amino acids (mmol/l)
|
0 to 8 hours after the test meal
|
|
Plasma glucose in blood in response to the ingestion of 15N fava bean
Time Frame: 0 to 8 hours after the test meal
|
plasma glucose (mmol/l)
|
0 to 8 hours after the test meal
|
|
Plasma insulin in blood in response to the ingestion of 15N fava bean
Time Frame: 0 to 8 hours after the test meal
|
plasma insulin (pmol/l)
|
0 to 8 hours after the test meal
|
|
Ileal microbiota
Time Frame: -0.5 h before the meal
|
Microbial DNA sequencing
|
-0.5 h before the meal
|
|
Peptide composition of ileal digesta
Time Frame: 0-8 h after the test meal
|
Peptidomic anlaysis by LC-MS
|
0-8 h after the test meal
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert Benamouzig, MD, PhD, Assistance Publique - Hopitaux de Paris
- Study Director: Claire Gaudichon, PhD, Prof, INRAE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- GIANT LEAPS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Protein Quality of Chlorella and Fababean Meat Analogue
-
Wageningen UniversityTop Institute Food and NutritionCompletedIdentify New Biomarkers in Blood or Urine After Consumption of Meat Protein, Dairy Protein and Grain Protein in Healthy Subjects.Netherlands
-
Société des Produits Nestlé (SPN)RecruitingCow Milk Protein AllergyGermany, Italy, Poland
-
University of AarhusUniversity of CopenhagenCompletedQuality of Life | Weight | Activities of Daily Living | Energy Intake | Protein Intake | Fluid Balance | Lean Body Mass | Fat MassDenmark
-
Cairo UniversityNot yet recruitingMuscle Strength | Quality of Life (QOL) | Joint Position Sense | Hemophilia aEgypt
-
PeriPharmCompletedMultiple Myeloma | Caregiver Subjective Burden | Quality of Life (QOL)Canada
-
Technical University of MunichMedical University of Vienna; University Medicine Greifswald; Fresenius Kabi; Berlin... and other collaboratorsRecruitingQuality of Life | Muscle Atrophy | Metabolic Disturbance | ICU Acquired Weakness | Energy Malnutrition Protein | Morphological and Microscopic FindingsGermany, Austria
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMonoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell MyelomaUnited States
-
Hacettepe UniversityCompleted
-
Ain Shams UniversityRecruitingMethotrexate | C Reactive Protein | Rheumatoid Arthritis (RA) Prevention | Rheumatic Arthritis | Anti Oxidative Stress | Quality of Life Outcomes | Anti Aging | Antioxidant | InflamationEgypt
-
The League of Clinical Research, RussiaCompletedHemophilia ARussian Federation